Cascade testing in mitochondrial diseases: a cross-sectional retrospective study.

Genetic screening within families provides a pathway for early intervention in hereditary conditions. Prior research has shown that identifying at-risk biological relatives through systematic screening improves clinical outcomes. Mitochondrial disorders present unique challenges due to diverse inheritance mechanisms involving both nuclear and mitochondrial genomes. These conditions often manifest with extreme phenotypic variability, making early detection difficult without targeted genetic insights. Improved surveillance and the timely introduction of clinical management are essential for at-risk biological relatives of those with confirmed organelle-based conditions. Existing literature lacks comprehensive data regarding the economic burden and actual participation rates in these screening programs. This absence of evidence motivated the current investigation into the feasibility and financial implications of family-wide genetic assessments.

This investigation evaluates the effectiveness and economic viability of systematic family screening for mitochondrial pathologies. Researchers sought to establish a robust framework for identifying relatives eligible for genetic assessment based on specific inheritance models. The project aimed to compare the theoretical eligibility of first-degree relatives against the actual participation observed in a clinical setting. Assessing the financial disparity between diagnosing an initial index case and testing subsequent family members formed a core objective. The team analyzed how different genetic variants, including Mitochondrial DNA (mtDNA) and Nuclear DNA (nDNA) mutations, influenced testing behavior. Quantifying the clinical status of relatives at the time of diagnosis provided insight into the utility of predictive screening. The study also sought to provide a clear framework that clinicians can use to guide their family-based testing efforts in daily practice.

Investigators conducted a cross-sectional retrospective study utilizing patient records from the Adult Mitochondrial Disease Clinic in Sydney. The cohort comprised 99 participants whose genetic profiles served as the basis for identifying at-risk kin. A retrospective chart review facilitated the extraction of phenotypic data and inheritance trajectories for each index case. The protocol categorized relatives into four distinct groups based on variant types: mtDNA Single Nucleotide Variants (SNVs) in males or females, and Autosomal Dominant (AD) or Autosomal Recessive (AR) nDNA variants. For males with mtDNA SNVs, the study identified siblings and mothers as eligible, while for females, the list expanded to include offspring. AD nDNA variants required screening of siblings, offspring, and both parents, whereas AR nDNA variants focused solely on siblings. Statistical analysis compared the mean costs of initial diagnostic sequencing against the expenses incurred during targeted predictive testing.

Participation in genetic screening reached 55.2% for the mtDNA group and 55.8% for the AD nDNA group, while the AR nDNA group showed 0% uptake. Among relatives in the mtDNA cohort who completed testing, 65.4% exhibited clear symptoms, whereas 14.1% remained entirely asymptomatic. Oligosymptomatic individuals accounted for 20.5% of the tested relatives within the mitochondrial DNA category. Financial analysis revealed that the mean cost for testing eligible relatives in the mtDNA group was $694.7, significantly lower than the $4578.4 required for index cases. Similar cost reductions appeared in the AD nDNA group, where relative testing cost $899.1 compared to $5715.1 for the primary diagnosis (p < 0.001). These findings demonstrate that targeted family screening is substantially more cost-effective than the initial broad diagnostic approach. The researchers noted that the cost of genetic diagnosis for index cases was consistently higher across all inheritance categories.

Systematic family screening facilitates the early identification of at-risk individuals, enabling timely clinical management and surveillance. The study confirms that the demand for genetic assessment fluctuates significantly based on the specific genotype and inheritance pattern involved. Multiple factors beyond simple eligibility influence the real-time participation of biological relatives in these diagnostic programs. Confirming diagnoses in symptomatic relatives allows for the immediate implementation of tailored care strategies. Future clinical frameworks must account for the high prevalence of oligosymptomatic and asymptomatic carriers identified through these methods. Integrating cost-effective predictive testing into standard practice could optimize resource allocation within mitochondrial medicine. The implementation of these surveillance strategies at an early stage of the disease is vital for improving long-term patient outcomes.